New drug aims to protect lungs in autoimmune patients
NCT ID NCT07495033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether the drug telitacicept can slow the decline in lung function in people with connective tissue disease-related interstitial lung disease (CTD-ILD). About 260 adults with conditions like rheumatoid arthritis or lupus and confirmed lung scarring will receive either telitacicept or a placebo for 52 weeks. The main goal is to see if the drug helps preserve lung volume.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- telitacicept
- What this could lead to
- If successful, this could provide a new treatment option to slow lung damage in people with connective tissue disease-related lung disease.
- What could go wrong
- This is a Phase 3 trial, but results may not confirm benefit. The drug could cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTD-ILD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.